Our leadership team
A diverse leadership team with the experience to scale, giving the best to our teams, partners and patients.
Manuel O. Méndez
Chief Executive Officer
Dr. Christian Fischer
Chief Scientific & Medical Officer
Sophie Bechu
Chief Operating Officer
Dr. Michael Hausmann
Chief Technology Officer
Viviane Montarnal
General Counsel & Compliance Officer
Steven Zuiderwijk
Chief Strategy & Marketing Officer
Mark Wheeler
Head of Commercial & Customer Success
David TenBarge
General Manager, Transfusion Business
Matt Howson
Chief Manufacturing Operations Officer, Clinical Business
Erika Abondano
Chief People Officer
Mario Wijker
Chief Quality & Regulatory Affairs Officer
Mark Wheeler
Head of Commercial
Latest News
Recent press, briefings and insights helping you stay informed on AliveDx news.
-
AliveDx Achieves NHS UK Evergreen Level 2 in Annual Sustainability Assessment
AliveDx is proud to announce that we have successfully completed the 2025/26 NHS Evergreen Sustainable Supplier Assessment, achieving Level 2 status in the UK. This annual assessment is a key benchmark for suppliers to the NHS in the UK, measuring
-
AliveDx & Medipac Technologies Ltd: Distribution Agreement Announcement
AliveDx Suisse S.A. is pleased to announce the signing of a strategic distribution agreement with Medipac Technologies Ltd, a leading healthcare-solutions provider in Bangladesh. Under this partnership, Medipac Technologies Ltd will distribute AliveDx’s innovative MosaiQ® and LumiQ® diagnostic platforms across Bangladesh, effective immediately. This collaboration strengthens AliveDx’s commitment to expanding
-
AliveDx featured in The Guardian newspaper as one of the UK’s Best Workplaces in Biopharma
Following our recent announcement that AliveDx had been shortlisted, we’re proud to confirm that we’ve now been officially recognised as one of the UK’s Best Workplaces in Biopharma with the list now published in The Guardian. This recognition places AliveDx
-
AliveDx named one of the UK’s Best Workplaces in BioPharma™ 2025
We’re proud to announce that AliveDx has been officially recognised as one of the UK’s Best Workplaces in BioPharma™ 2025 by Great Place to Work® UK. This is a prestigious honour that places us among the top 30 biopharma companies
-
AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.
Eysins, Switzerland, September 2nd, 2025 AliveDx, the global in-vitro diagnostics company that aims to transform patient care, today announces that it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Vasculitis (VAS)
-
AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions. Eysins, Switzerland – August 25, 2025 – AliveDx, the global in-vitro diagnostics company dedicated to advancing
